[{"id":"d7a99f87-af15-49c9-a79c-a263479ceeab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05219513","created_at":"2022-02-05T18:28:39.448Z","updated_at":"2024-07-02T16:34:26.627Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05219513","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • RG6333"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-06-13"},{"id":"d08b3f2e-b940-4c34-82e7-531cd52cc0cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401020","created_at":"2023-02-21T20:01:15.546Z","updated_at":"2024-07-02T16:35:03.034Z","phase":"Phase 1","brief_title":"First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","source_id_and_acronym":"NCT04401020","lead_sponsor":"Sanofi","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SAR442257"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 03/02/2024","primary_completion_date":" 03/02/2024","study_txt":" Completion: 08/14/2024","study_completion_date":" 08/14/2024","last_update_posted":"2024-05-17"},{"id":"1bc7d467-7896-491d-8c0c-8c4bb935a5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972657","created_at":"2023-08-08T17:08:39.649Z","updated_at":"2024-07-02T16:35:15.522Z","phase":"Phase 1/2","brief_title":"A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","source_id_and_acronym":"NCT03972657","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/03/2026","study_completion_date":" 07/03/2026","last_update_posted":"2024-03-08"},{"id":"d518557a-eea1-4a79-acfc-244bfd4c8285","acronym":"","url":"https://clinicaltrials.gov/study/NCT06037018","created_at":"2023-09-14T15:13:31.451Z","updated_at":"2024-07-02T16:35:36.987Z","phase":"Phase 1","brief_title":"Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies","source_id_and_acronym":"NCT06037018","lead_sponsor":"CytoCares Inc","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD19 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-09-14"}]